These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

74 related items for PubMed ID: 10659600

  • 1. [Treatment of multiple sclerosis].
    Fernández Uría D.
    Neurologia; 1999 Dec; 14 Suppl 6():1-12. PubMed ID: 10659600
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. [Is immunosuppression a future therapeutic strategy for multiple sclerosis?].
    Edan G, Coustans M.
    Pathol Biol (Paris); 2000 Mar; 48(2):114-20. PubMed ID: 10815287
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Multiple sclerosis: interferon beta for some serious forms.
    Prescrire Int; 2007 Dec; 16(92):252-7. PubMed ID: 18092425
    [Abstract] [Full Text] [Related]

  • 6. Multiple sclerosis. II. A critical assessment of immunotherapy.
    Durelli L, Bergamini L.
    Riv Neurol; 1989 Dec; 59(5):191-201. PubMed ID: 2483962
    [Abstract] [Full Text] [Related]

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM, Leucht S, Carpenter D, Docherty JP, Expert Consensus Panel for Optimizing Pharmacologic Treatment of Psychotic Disorders.
    J Clin Psychiatry; 2003 May; 64 Suppl 12():5-19. PubMed ID: 14640142
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Multiple sclerosis: treatment and prevention of relapses and progression in multiple sclerosis].
    Saida T.
    Rinsho Shinkeigaku; 2004 Nov; 44(11):796-8. PubMed ID: 15651294
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M, Ghezzi A, Comi G.
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [Abstract] [Full Text] [Related]

  • 15. Treatment of progressive forms of multiple sclerosis by cyclophosphamide: a cohort study of 490 patients.
    Zephir H, de Seze J, Duhamel A, Debouverie M, Hautecoeur P, Lebrun C, Malikova I, Pelletier J, Sénéchal O, Vermersch P.
    J Neurol Sci; 2004 Mar 15; 218(1-2):73-7. PubMed ID: 14759636
    [Abstract] [Full Text] [Related]

  • 16. [Long-term immunosuppression in multiple sclerosis: evaluation of treatments begun before 1972].
    Sabouraud O, Oger J, Darcel F, Madigand M, Merienne M.
    Rev Neurol (Paris); 1984 Mar 15; 140(2):125-30. PubMed ID: 6710012
    [Abstract] [Full Text] [Related]

  • 17. [Rationale for an early treatment of multiple sclerosis].
    Comi G, Martino G.
    Rev Neurol; 1984 Mar 15; 30(12):1265-8. PubMed ID: 10935262
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Recent progress in treatment for multiple sclerosis].
    Kira J.
    Rinsho Shinkeigaku; 2000 Dec 15; 40(12):1261-3. PubMed ID: 11464473
    [Abstract] [Full Text] [Related]

  • 20. Cyclosporine and multiple sclerosis: the cons.
    Rudge P.
    Neurology; 1988 Jul 15; 38(7 Suppl 2):29-30. PubMed ID: 3290712
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.